

## Medical & Clinical Case Reports Journal

<https://urfpublishers.com/journal/case-reports>

Vol: 3 & Iss: 3

Research Article

# **IκBα Inhibits Colorectal Cancer Progression by Suppressing Constitutive NF-κB Activation**

Xing Liu\*

The Affiliated First Hospital of Fuyang Normal University, China

**Citation:** Liu X. IκBα Inhibits Colorectal Cancer Progression by Suppressing Constitutive NF-κB Activation. *Medi Clin Case Rep J* 2025;3(3):1309-1311. DOI: doi.org/10.51219/MCCRJ/Xing-Liu/363

**Received:** 07 January, 2025; **Accepted:** 11 February, 2025; **Published:** 15 March, 2025

**\*Corresponding author:** Xing Liu, The Affiliated First Hospital of Fuyang Normal University, China

**Copyright:** © 2025 Liu X., This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### **ABSTRACT**

**Objective:** To explore the role of IκBα (inhibitor of nuclear factor kappa B alpha) in colorectal cancer (CRC) cell proliferation, migration, invasion and its regulatory effect on the NF-κB signaling pathway.

**Methods:** IκBα expression was detected in CRC cell lines (HCT116, SW480) and normal colonic epithelial cell line (NCM460) by Western blot and qRT-PCR. IκBα was overexpressed via plasmid or knocked down via siRNA in HCT116 cells. Cell proliferation (CCK-8), migration (scratch assay), invasion (Transwell) and NF-κB-related proteins (p-p65, IκBα, TNF-α) were analyzed.

**Results:** IκBα was downregulated in CRC cells compared with NCM460 ( $P<0.01$ ). IκBα overexpression reduced HCT116 cell proliferation (OD450 at 72h:  $0.65\pm0.06$  vs.  $1.29\pm0.12$ ,  $P<0.05$ ), migration rate ( $28.9\pm3.6\%$  vs.  $67.8\pm5.5\%$ ,  $P<0.01$ ) and invasive cell number ( $40\pm5$  vs.  $123\pm10$ ,  $P<0.01$ ), while decreasing p-p65 and TNF-α expression ( $P<0.05$ ). IκBα knockdown showed opposite effects.

**Conclusion:** IκBα functions as a tumor suppressor in CRC by inhibiting NF-κB activation, serving as a potential therapeutic target.

**Keywords:** Colorectal Cancer; Cell Proliferation; Transwell; CRC Cell Lines

### **Introduction**

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths globally, with ~935,000 annual fatalities<sup>1</sup>. The NF-κB signaling pathway is constitutively activated in over 60% of advanced CRC cases, driving tumor cell survival, invasion and inflammation<sup>2</sup>. IκBα, encoded by the NFKBIA gene, is the primary endogenous inhibitor of NF-κB: it sequesters p65/p50 complexes in the cytoplasm, preventing nuclear translocation and oncogenic gene transcription<sup>3,4</sup>. Clinical studies have shown that IκBα expression is downregulated in CRC tissues, correlating with lymph node metastasis and poor prognosis<sup>5,6</sup>.

However, the functional role of IκBα in CRC cell behaviors and its mechanism of regulating NF-κB remain to be fully clarified. This study uses CRC cell lines to verify IκBα's effect on tumor progression and its association with NF-κB signaling.

### **Materials and Methods**

#### **Cell culture**

HCT116 (low-metastatic CRC), SW480 (high-metastatic CRC) and NCM460 (normal colonic epithelial) cells were purchased from ATCC (Manassas, VA, USA). Cells were cultured in RPMI-1640 medium (Gibco, Grand Island, NY,

USA) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37°C in a 5% CO<sub>2</sub> incubator. For NF-κB stimulation, cells were treated with 10 ng/mL recombinant human TNF-α (R&D Systems, Minneapolis, MN, USA) for 24h.

### Transfection

IκBα overexpression plasmid (pcDNA3.1-IκBα) and empty vector were obtained from Addgene (Cambridge, MA, USA). IκBα siRNA (si-IκBα) and negative control siRNA (si-NC) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). HCT116 cells (5×10<sup>5</sup> cells/well) were seeded in 6-well plates and transfected with plasmids/siRNA using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) at 60-70% confluence. IκBα expression was verified by Western blot and qRT-PCR 48h post-transfection.

### qRT-PCR and western blot

**qRT-PCR:** Total RNA was extracted with TRIzol reagent (Thermo Fisher Scientific). cDNA was synthesized using PrimeScript RT Kit (Takara, Kyoto, Japan). IκBα primers: Forward 5'-ATGGACTACAGGGACGACCT-3', Reverse 5'-TCAGCTGGGTTCTGTTTC-3'; GAPDH primers (internal control): Forward 5'-GAAGGTGAAGGTCGGAGTC-3', Reverse 5'-GAAGATGGTGATGGGATTTC-3'. Relative expression was calculated via the 2<sup>-ΔΔCt</sup> method.

**Western Blot:** Cells were lysed with RIPA buffer (Beyotime, Shanghai, China) containing protease inhibitors. Protein concentration was measured by BCA assay (Beyotime). Equal amounts of protein (30μg) were separated by 10% SDS-PAGE, transferred to PVDF membranes (Millipore, Billerica, MA, USA) and probed with primary antibodies against IκBα, p-p65 (Ser536), TNF-α (Cell Signaling Technology, Danvers, MA, USA) and GAPDH (Beyotime) at 4°C overnight. Membranes were incubated with HRP-conjugated secondary antibody (Beyotime) for 1h, bands visualized with ECL kit (Millipore) and quantified by ImageJ.

### Functional assays

- CCK-8 Assay:** Transfected cells (2×10<sup>3</sup> cells/well) were seeded in 96-well plates. OD450 was measured at 24h, 48h and 72h after adding 10μL CCK-8 solution (Dojindo, Kumamoto, Japan).
- Scratch Wound Healing Assay:** Confluent cells were scratched with a 200μL pipette tip. Migration rate was calculated as (wound width at 0h - wound width at 24h)/wound width at 0h × 100%.
- Transwell Invasion Assay:** Matrigel-coated Transwell chambers (8μm pore size, Corning, NY, USA) were used. Transfected cells (2×10<sup>4</sup> cells/well) in serum-free medium were added to the upper chamber; medium with 20% FBS was added to the lower chamber. Invasive cells were counted at 24h.

### Statistical analysis

Data were presented as mean ± standard deviation (SD, n=3). Statistical analysis was performed using SPSS 26.0 software (IBM, Armonk, NY, USA) with independent samples t-test. P<0.05 was considered statistically significant.

## Results

### IκBα is downregulated in CRC cell lines

qRT-PCR showed IκBα mRNA expression in HCT116 and SW480 cells was 0.26±0.03 and 0.33±0.04 folds of NCM460, respectively (P<0.01). Western blot revealed IκBα protein levels in HCT116 (0.29±0.04) and SW480 (0.36±0.05) were significantly lower than NCM460 (1.00±0.10, P<0.01), with SW480 showing higher IκBα downregulation than HCT116.

### IκBα inhibits CRC cell proliferation

In HCT116 cells, IκBα overexpression reduced OD450 at 48h (0.53±0.06 vs. 0.88±0.08, P<0.05) and 72h (0.65±0.06 vs. 1.29±0.12, P<0.05). IκBα knockdown increased OD450 at 48h (1.06±0.09 vs. 0.87±0.07, P<0.05) and 72h (1.37±0.13 vs. 1.25±0.10, P<0.05). TNF-α stimulation failed to rescue proliferation inhibition in IκBα-overexpressing cells.

### IκBα suppresses CRC cell migration and invasion

Scratch assay showed IκBα overexpression reduced HCT116 migration rate to 28.9±3.6% (vs. 67.8±5.5% in control, P<0.01). Transwell assay revealed IκBα overexpression decreased invasive cell number to 40±5 (vs. 123±10 in control, P<0.01). IκBα knockdown showed opposite effects: migration rate increased to 73.5±5.8% (vs. 66.2±5.3% in si-NC, P<0.01) and invasive cells increased to 135±12 (vs. 120±9 in si-NC, P<0.01).

### IκBα inhibits NF-κB signaling activation

IκBα overexpression upregulated total IκBα protein (2.00±0.19 vs. 1.00±0.09, P<0.05) and downregulated p-p65 (0.42±0.04 vs. 1.00±0.08, P<0.05) and TNF-α (0.39±0.04 vs. 1.00±0.07, P<0.05). IκBα knockdown decreased total IκBα (0.45±0.05 vs. 1.00±0.09, P<0.05) and increased p-p65 (1.88±0.17 vs. 1.00±0.08, P<0.05) and TNF-α (1.82±0.16 vs. 1.00±0.07, P<0.05).

## Discussion

This study confirms IκBα is downregulated in CRC cells and its overexpression inhibits proliferation, migration and invasion by suppressing NF-κB activation-consistent with its tumor-suppressive role in gastric and pancreatic cancer<sup>7,8</sup>. Mechanistically, IκBα sequesters p65 in the cytoplasm, preventing its nuclear translocation and transcription of pro-oncogenic genes (e.g., TNF-α)<sup>4</sup>. Limitations include lack of in vivo validation; future studies should explore IκBα's crosstalk with Wnt/β-catenin, a key pathway in CRC<sup>9</sup>. Restoring IκBα expression (e.g., via NFKBIA gene delivery) may be a promising strategy for CRC treatment<sup>10</sup>.

## Conclusion

IκBα is downregulated in colorectal cancer cell lines and inhibits CRC progression by suppressing the NF-κB signaling pathway, highlighting its potential as a therapeutic target for CRC.

## References

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209-249.
2. Karin M, Greten FR. NF-κB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2008;8(11):810-820.

3. Hayden MS, Ghosh S. Shared principles in NF-κB signaling. *Cell* 2008;132(3):344-362.
4. Baldwin AS Jr. The NF-κB and IκB proteins: New discoveries and insights. *Annu Rev Immunol* 1996;14:649-683.
5. Liu Y, Li J, Zhang H, et al. NFKBIA downregulation correlates with poor prognosis and NF-κB activation in colorectal cancer. *Oncol Rep* 2022;50(7):313.
6. Chen Y, Li D, Zhang H, et al. IκBα expression predicts clinical outcome in patients with stage II/III colorectal cancer. *Mol Cell Biochem* 2021;479(7):947-958.
7. Zhao J, Wang C, Li J, et al. IκBα restoration inhibits gastric cancer cell invasion via suppressing NF-κB-mediated MMP-9 expression. *Cell Biol Int* 2023;47(12):1578-1587.
8. Park J, Kim J, Lee S, et al. IκBα overexpression reduces pancreatic cancer stem cell properties by inhibiting NF-κB signaling. *Exp Mol Med* 2023;55(12):1703-1716.
9. Wang X, Zhang Y, Li D, et al. Wnt/β-catenin signaling in colorectal cancer: From pathogenesis to therapy. *Signal Transduct Target Ther* 2021;6(1):343.
10. Huang Y, Ye X, Li D, et al. Targeting NF-κB signaling in colorectal cancer: Current status and future perspectives. *Drug Des Devel Ther* 2023;17(1):3829-3844.